Wolverine Trading, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Wolverine Trading, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $61,556 - $67,545	-1,580 Reduced 12.37%	11,198 $457,000
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $122,312 - $129,463	-2,992 Reduced 18.97%	12,778 $540,000
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $319,657 - $669,278	15,770 New	15,770 $668,000
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $204,969 - $317,244	8,982 New	8,982 $215,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.